Pharmacia & Upjohn (PNU) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacia & Upjohn (PNU)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Earl Graham who wrote ()	3/25/1998 3:26:00 PM
From: Goolie2	Read Replies (1) of 43

Sex appeal it ain't got. But a story and good technical action it sure does have. * New CEO Fred Hassan hired from AHP to turn this puppy around. By most analysis I have read, he has stopped the bleeding, and 1998 will be the turnaround year. Fred has had little difficulty in recuiting from AHP. That and the fact that PNU is moving it's headquarters to NJ (AHP's backyard) would lead to the natural assumption that PNU will be taken out by AHP. * Fred bought 107,000 shares of PNU last August at $37. Many of his managers are doing the same. * 4 Potential blockbuster drugs are due out this year, first of which is Detrol, already approved in europe with impressive ramp up in sales. For treatment of incontenence without "dry mouth". * Stock has been a favorite of patient value investors and few others (Note few posts on this thread) The stock offers an above average yield but until today, it couldn't take out the old $44 5/8 high which has stood from 1996. * The stock is rated "A" accumulation in IBD, and RS has been rising, almost to the magic "70" which I have found seems to be required before the afterburners kick in. In closing, you have the only large cap pharmacuetical with a smallish cap of about $20Billion. Either a takeout or a fundamental recovery, this stock looks ready to move much higher. You have a CEO that has been hand picked by the Board and charged with the mission of either pulling PNU out of the Devil's Spiral or put this puppy on the block. His compensation is heavily weighted with incentives for stock performance. You have a four new drugs comming out of what had been a poor development pipeline. You have extremely low expectations, and earnings estimates should be blown away assuming Detrol approval and sales ramp up in the next few weeks. Good luck to longs Goolie

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next